1
|
Asunis F, De Gioannis G, Francini G, Lombardi L, Muntoni A, Polettini A, Pomi R, Rossi A, Spiga D. Environmental life cycle assessment of polyhydroxyalkanoates production from cheese whey. Waste Manag 2021; 132:31-43. [PMID: 34304020 DOI: 10.1016/j.wasman.2021.07.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 06/30/2021] [Accepted: 07/10/2021] [Indexed: 06/13/2023]
Abstract
Cheese whey (CW) is the main by-product of the dairy industry and is often considered one of the main agro-industrial biowaste streams to handle, especially within the European Union, where the diary activities play an essential role in the agrarian economy. In the paper, Life Cycle Assessment (LCA) is used to analyse the feasibility of producing polyhydroxyalkanoates (PHA) as the main output of an innovative CW valorisation route which is benchmarked against a conventional anaerobic digestion (AD) process. To this aim, the LCA inventory data are derived from lab-scale PHA accumulation tests performed on real CW, while data from the literature of concern are used for modelling both the PHA extraction from the accumulating biomass and for the alternative CW valorisation through AD. The comparison shows that AD would have better environmental performances than the baseline PHA production scenario. For example, the climate change indicator values result 44.8 and -35.7 kg CO2 eq./t CW for the baseline PHA recovery and AD, respectively. LCA proved to be a useful tool to highlight the weak points of innovative processes and suggest proper improvements. Once improved and again analysed through the LCA, the PHA production process from CW shows that environmental performance comparable to AD may be achieved. With reference, again, to the climate change indicator the value can be reduced to -50.3 kg CO2 eq./t CW for the improved PHA production process.
Collapse
Affiliation(s)
- Fabiano Asunis
- Department of Civil and Environmental Engineering and Architecture, University of Cagliari, Via Marengo 2, 09123 Cagliari, Italy
| | - Giorgia De Gioannis
- Department of Civil and Environmental Engineering and Architecture, University of Cagliari, Via Marengo 2, 09123 Cagliari, Italy; IGAG - CNR, Istituto di Geologia Ambientale e Geoingegneria - Consiglio Nazionale delle Ricerche, Piazza d'Armi, 09123 Cagliari, Italy
| | - Giovanni Francini
- Department of Civil and Environmental Engineering, University of Florence, Via Santa Marta 3, 50139 Florence, Italy
| | - Lidia Lombardi
- Niccolò Cusano University of Rome, Via Don Carlo Gnocchi 3, 00166 Rome, Italy.
| | - Aldo Muntoni
- Department of Civil and Environmental Engineering and Architecture, University of Cagliari, Via Marengo 2, 09123 Cagliari, Italy
| | - Alessandra Polettini
- Department of Civil and Environmental Engineering, University of Rome "La Sapienza", Via Eudossiana 18, 00184 Rome, Italy
| | - Raffaella Pomi
- Department of Civil and Environmental Engineering, University of Rome "La Sapienza", Via Eudossiana 18, 00184 Rome, Italy
| | - Andreina Rossi
- Department of Civil and Environmental Engineering, University of Rome "La Sapienza", Via Eudossiana 18, 00184 Rome, Italy
| | - Daniela Spiga
- Department of Civil and Environmental Engineering and Architecture, University of Cagliari, Via Marengo 2, 09123 Cagliari, Italy
| |
Collapse
|
2
|
Vosooghnia A, Polettini A, Rossi A, Vázquez-Rowe I, Francini G. Carbon footprint of anaerobic digestion combined with ultrasonic post-treatment of agro-industrial organic residues. J Environ Manage 2021; 278:111459. [PMID: 33120089 DOI: 10.1016/j.jenvman.2020.111459] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 09/14/2020] [Accepted: 09/28/2020] [Indexed: 06/11/2023]
Abstract
Anaerobic digestion (AD) of organic waste, although widely practiced, may require suitable accompanying treatments to enhance the degradability of complex materials. Since these may require significant efforts in terms of energy and chemical demand, careful assessment of their overall environmental sustainability is mandatory to evaluate their full-scale feasibility. The study aims to represent the environmental profile of ultrasonication (US) applied as a post-treatment of anaerobic digestion of agro-industrial organic residues. There is an interest in the US treatment for the processing of complex organic materials prior to AD in order to enhance the hydrolysis of complex organic substrates and increase the biogas yield of the biological process. An attributional, process-based life cycle assessment (LCA) study was applied to quantify and compare the potential environmental impacts of an AD plant, the biogas utilization options as well as the different digestate processing alternatives grouped into a set of 16 scenarios. Based on the results, upgrading of biogas and bio-methane use as vehicle fuel instead of energy generation from CHP or fuel cell was recommended due to the lower impact on GWP. Similarly, composting was a suitable option to reduce environmental impacts compared to belt drying. From the uncertainty analysis, AD without US as post-treatment proves to be more sustainable in terms of GWP compared to when US is used, showing net savings in GHG emissions especially when upgrading of biogas is applied. The analysis provides useful indications to policy makers to define sustainable management alternatives for organic residues as well as identify the environmental advantages associated with biogas utilization and digestate treatment and disposal alternatives.
Collapse
Affiliation(s)
- Alireza Vosooghnia
- Department of Civil and Environmental Engineering, University of Rome "La Sapienza", Via Eudossiana 18, I-00184, Rome, Italy.
| | - Alessandra Polettini
- Department of Civil and Environmental Engineering, University of Rome "La Sapienza", Via Eudossiana 18, I-00184, Rome, Italy
| | - Andreina Rossi
- Department of Civil and Environmental Engineering, University of Rome "La Sapienza", Via Eudossiana 18, I-00184, Rome, Italy
| | - Ian Vázquez-Rowe
- Peruvian Life Cycle Assessment Network (PELCAN), Department of Engineering, Pontificia Universidad Católica del Perú, Av. Universitaria 1801, San Miguel, 15088, Lima, Peru
| | - Giovanni Francini
- Department of Civil and Environmental Engineering, University of Florence, Via Santa Marta 3, 50139, Florence, Italy
| |
Collapse
|
3
|
Correale P, Staropoli N, Pastina P, Giannicola R, Botta C, Francini E, Ridolfi L, Mini E, Ciliberto D, Agostino R, Strangio A, Azzarello D, Nardone V, Falzea A, Tassone P, Giordano A, Pirtoli L, Francini G, Tagliaferri P. GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Francini G, Montagnani M, Petrioli R, Paffetti P, Marsili S, Leone V. Comparison between CEA, TPA, CA 15/3 and Hydroxyproline, Alkaline Phosphatase, Whole Body Retention of 99mTc MDP in the follow-up of Bone Metastases in Breast Cancer. Int J Biol Markers 2018; 5:65-72. [PMID: 2283479 DOI: 10.1177/172460089000500203] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The development of bone metastases in cancer can be monitored easily using three markers: 24 h urinary hydroxyproline excretion (HOP) (an index of osteoclastic activity), serum alkaline phosphatase (Alk.Ph.) (an index of osteoblastic activity) and 24 h whole body retention of 99mTc-methylene diphosphonate (WBR%) (an index of bone turnover). To evaluate the effectiveness of this group of bone tumor markers in breast cancer we compared it with the following group of three markers which are commonly used in the monitoring of breast cancer and in the follow-up of advanced disease with or without bone metastases: carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and breast carcinoma antigen (CA 15/3). In 48 patients with bone metastases CEA, TPA and CA 15/3 were shown to be sensitive (79%, 85%, 90% respectively), while HOP, Alk.Ph. and WBR%, which are commonly accepted as reliable markers of bone activity, showed a lower sensitivity (67%, 46%, 75% respectively). These results may be explained by the lack of osteoclastic or osteoblastic (or both) activity at the time of diagnosis. This explanation is supported by the fact that the bone markers HOP, Alk.Ph. and WBR% were found to be more sensitive than the others in the subsequent follow-up study. We conclude that in our study, CEA, TPA and CA 15/3 are at first more sensitive than Alk. Ph., HOP and WBR% but during the follow-up Alk.Ph., HOP and WBR% are possibly both more specific and more sensitive
Collapse
Affiliation(s)
- G Francini
- Division of Clinical Oncology, University of Siena, Italy
| | | | | | | | | | | |
Collapse
|
5
|
Lorenzi M, Vindigni C, Minacci C, Tripodi SA, Iroatulam A, Petrioli R, Francini G. Histopathological and Prognostic Evaluation of Immunohistochemical Findings in Colorectal Cancer. Int J Biol Markers 2018; 12:68-74. [PMID: 9342635 DOI: 10.1177/172460089701200205] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Many immunohistochemical studies have investigated the relationship between immunohistochemical characteristics and histopathological findings in colorectal tumors. One of the most extensively studied markers has been tissue CEA, although the prognostic significance of this and other antigens is still uncertain. The authors report results relative to three tumoral antigens (carcinoembryonic antigen, CEA; tissue polypeptide antigen, TPA, and carbohydrate antigen 19–9, CA 19–9) determined by immunohistochemical methods in tissue samples of 52 colorectal carcinomas. The relationship between the immunohistochemical characteristics of the neoplasms and the clinicopathologic parameters, as well as their influence on the prognosis of the patients, were examined. Positive CEA reaction has a significant relationship with grade of differentiation of the tumor while diffuse cellular expression of this antigen often indicates neoplasms extending beyond the intestinal wall and invading the lymph vessels. The number of tissue antigens expressed is significantly related to the extent of tumor spread through the intestinal wall. A greater incidence of recurrence and shorter disease-free interval and survival were observed in neoplasms that expressed tissue TPA antigen or more than one tissue antigens. In the present study the latter parameter has demonstrated to have independent prognostic significance for the disease-free interval. Immunohistochemical evaluation of antigens in colorectal carcinoma tissue shows a possible independent prognostic value of the antigenic heterogeneity of tumors, which could be related to their different biological behavior.
Collapse
Affiliation(s)
- M Lorenzi
- Institute of General Surgery and Surgical Specialties, University of Siena, Italy
| | | | | | | | | | | | | |
Collapse
|
6
|
Setälä H, Francini G, Allen JA, Jumpponen A, Hui N, Kotze DJ. Urban parks provide ecosystem services by retaining metals and nutrients in soils. Environ Pollut 2017; 231:451-461. [PMID: 28830018 DOI: 10.1016/j.envpol.2017.08.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 08/02/2017] [Accepted: 08/02/2017] [Indexed: 05/17/2023]
Abstract
Urban greenspaces provide ecosystem services like more natural ecosystems do. For instance, vegetation modifies soil properties, including pH and soil organic matter content, yet little is known about its effect on metals. We investigated whether the accumulation and mobility of heavy metals, nutrients and carbon is affected by plant functional types (evergreen or deciduous trees, lawns) in urban parks of varying ages in southern Finland. Plant types modified soil physico-chemical parameters differently, resulting in diverging accumulation and mobility of metals and other elements in park soils. However, the effects of plant functional type depended on park age: lawns in parks of ca. 50 y old had the highest contents of Cr, Cu, Fe, Mn, Ni, and Zn, and in these, and older parks (>100 y old), contents of most metals were lowest under evergreen trees. The mobility of metals and other elements was influenced by the amount of water leached through the soils, highlighting the importance of vegetation on hydrology. Soils under evergreen trees in young parks and lawns in intermediately-aged parks were most permeable to water, and thus had high loads of Ca, Cr, Cu, Fe, Ni, tot-P and tot-N. The loads/concentrations of elements in the leachates was not clearly reflected by their content/concentration in the soil, alluding to the storage capacity of these elements in urban park soils. Our results suggest that in urban systems with a high proportion of impermeable surfaces, park soil has the potential to store nutrients and metals and provide an important ecosystem service particularly in polluted cities.
Collapse
Affiliation(s)
- H Setälä
- Department of Environmental Sciences, University of Helsinki, FIN-15140 Lahti, Finland.
| | - G Francini
- Department of Environmental Sciences, University of Helsinki, FIN-15140 Lahti, Finland.
| | - J A Allen
- Department of Environmental Sciences, University of Helsinki, FIN-15140 Lahti, Finland.
| | - A Jumpponen
- Division of Biology, Kansas State University, Manhattan, KS 66506, USA.
| | - N Hui
- Department of Environmental Sciences, University of Helsinki, FIN-15140 Lahti, Finland.
| | - D J Kotze
- Department of Environmental Sciences, University of Helsinki, FIN-15140 Lahti, Finland.
| |
Collapse
|
7
|
Ardizzoni A, Bidoli P, Chiari R, Bonomi L, Turci D, Landi L, Toschi L, De Tursi M, Francini G, Giordano M, Alabiso O, De Censi A, Livi L, Berruti A, Minelli M, Ricevuto E, Illiano A, Puppo G, Delmonte A, Galetta D. MA 02.05 Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.454] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Cappuzzo F, Bidoli P, Chiari R, Chirco A, Turci D, Ardizzoni A, Santoro A, Natoli C, Francini G, Giordano M, Borra G, Defferrari C, Livi L, Berruti A, Minelli M, Ricevuto E, Illiano A, Puppo G, Delmonte A, Misino A. Real life experience with nivolumab in patients (pts) with advanced non-squamous NSCLC (nSq-NSCLC) exhibiting KRAS mutations: The Italian Expanded Access Program (EAP). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Rossi G, Martellucci I, Marsili S, Petrioli R, Nardone V, Chirra M, Torre P, Messutti L, Multari A, Francini G. Eribulin vs. Eribulin + Bevacizumab in advanced-line treatment of Her-2 negative metastatic breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Marsili S, Rossi G, Martellucci I, Chirra M, Messutti L, Torre P, Petrioli R, Francini G. The complex management and treatment of hydatidiform mole: our experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw338.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Martellucci I, Fanelli M, Cherri S, Multari A, Pesola G, Rosellini P, Ciompi A, Francini G. Pre-graduate internship in the medical oncology department: a good training setting to capture aspects of palliative and simultaneous care. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw336.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Miano S, Rossi G, Marsili S, Petrioli R, Pascucci A, Francini G. Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.67] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Martellucci I, Laera L, Lippi S, Marsili S, Petrioli R, Francini G. Impact of cannabinoids on the Quality of Life in Oncology: Prospective Observational Study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Petrioli R, Martellucci I, Rossi G, Marsili S, Tini P, Francini G. Effectiveness of Bevacizumab maintenance therapy associated with metronomic chemotherapy and hormone therapy after treatment with taxanes in patients with HER-2 negative metastatic breast cancer (mBC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Rossi G, Martellucci I, Marsili S, Senologico G, Francini G, Neri A. Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, Testi W, Tanzini G, Francini G. Biweekly Triple Combination Chemotherapy with Gemcitabine, Oxaliplatin, Levofolinic Acid and 5-Fluorouracil (GOLF) Is a Safe and Active Treatment for Patients with Inoperable Pancreatic Cancer. J Chemother 2013; 20:119-25. [DOI: 10.1179/joc.2008.20.1.119] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
17
|
Correale P, Cerretani D, Clerici M, Messinese S, Marsili S, Petrioli R, Cetta F, Savelli V, Guarnieri A, Pinto E, Giorgi G, Francini G. Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in Patients with Different Gastroenteric Malignancies. J Chemother 2013; 16:206-10. [PMID: 15216958 DOI: 10.1179/joc.2004.16.2.206] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
This phase II clinical trial was performed in order to evaluate the pharmacokinetics, toxicity and anti-tumor activity of a novel combination of gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) designed on a specific translational basis. Every 4 weeks, 44 patients with various gastroenteric malignancies, 29 of whom had pancreas carcinoma, received a short intravenous (i.v.) infusion of FA (100 mg/m2) and 5-FU (400 mg/m2) on days 1-5, and GEM 1000 mg/m2 on days 1, 8 and 16. Our results suggest that, although this treatment leads to hematological and gastroenteric toxicity, it is very active in patients with pancreatic carcinoma. We therefore believe that an improved version would merit further investigation in larger scale trials.
Collapse
Affiliation(s)
- P Correale
- Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Siena, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Licchetta A, Correale P, Migali C, Remondo C, Francini E, Pascucci A, Magliocca A, Guarnieri A, Savelli V, Piccolomini A, Carli A, Francini G. Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate. J Chemother 2013; 22:201-4. [DOI: 10.1179/joc.2010.22.3.201] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
19
|
Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis 2011; 13:846-52. [PMID: 20070327 DOI: 10.1111/j.1463-1318.2010.02206.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
AIM The simultaneous administration of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin (FOLFOXIRI) has been compared with standard 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) in randomized trials in metastatic colorectal cancer patients. A superior efficacy of FOLFOXIRI has been reported by some authors, but others have failed to show any differences and do not recommend its use because of greater cost and toxicity. We performed a systematic review of the literature to analyse efficacy and toxicity of FOLFOXIRI. METHOD Odds ratios (OR) with 95% confidence intervals (CI) were used to analyse dichotomous variables. Hazard ratios (HR) for progression and death were combined with an inverse variance method based on logarithmic conversion. A fixed-effect model and Mantel-Haenszel's method were used. Heterogeneity was tested with Cochrane's Q test and I(2) test. RESULTS A significant increase in response rate (OR 2.04; P < 0.01) was associated with treatment by FOLFOXIRI and a benefit was also shown by the HR for progression (HR 0.72; P < 0.01) and death (HR 0.71; P < 0.01). Analysis for toxicity found a significant increase associated with FOLFOXIRI except for anaemia, fatigue and febrile neutropenia. CONCLUSION FOLFOXIRI confers significant benefit in progression-free survival, survival, response and R0 resection rates but is more toxic compared with FOLFIRI.
Collapse
Affiliation(s)
- F Montagnani
- Oncology Unit, S. Giuseppe Hospital, Florence, Italy.
| | | | | | | | | |
Collapse
|
20
|
Shi Q, Hubbard JM, Yothers GA, Andre T, Saltz L, Francini G, Bot BM, Twelves C, Buyse ME, Grothey A, Sargent DJ. Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer 2011; 104:613-9. [PMID: 21285986 PMCID: PMC3049601 DOI: 10.1038/bjc.2011.5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2010] [Revised: 12/03/2010] [Accepted: 12/29/2010] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients. MATERIALS AND METHODS Patients were randomly assigned to D 30 mg m(-2) as intravenous infusion (i.v.) and EPI 30 mg m(-2) i.v. every week (D/EPI arm), or D 70 mg m(-2) i.v. every 3 weeks and oral P 5 mg twice daily (D/P arm). Chemotherapy was administered until disease progression or unacceptable toxicity. RESULTS A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The median progression-free survival (PFS) was 11.1 months (95% CI 9.2-12.6 months) in the D/EPI arm and 7.7 months (95% CI 5.7-9.4 months) in the D/P arm (P=0.0002). The median survival was 27.3 months (95% CI 22.1-30.8 months) in the D/EPI arm and 19.8 months (95% CI 14.4-24.8 months) in the D/P arm (P=0.003). Both regimens were generally well tolerated. CONCLUSION The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P.
Collapse
Affiliation(s)
- R Petrioli
- Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 2010; 22:1141-1146. [PMID: 21115601 DOI: 10.1093/annonc/mdq550] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND KRAS wild-type mutational status is necessary but not sufficient to get benefit from epidermal growth factor receptor inhibition. Predictive markers are currently being evaluated. In this study, we investigated early hypomagnesemia as a predictor of efficacy and outcome in terms of time to progression (TtP) and overall survival (OS) in a cohort of patients affected by advanced colorectal adenocarcinoma KRAS wild-type cetuximab-treated. PATIENTS AND METHODS One hundred and forty-three patients affected by stage IV colorectal adenocarcinoma KRAS wild type receiving cetuximab + irinotecan (CTX+IRI) as third-line anticancer treatment and resistant to oxaliplatin- and irinotecan-based chemotherapy were retrospectively included. Magnesium plasma levels were measured before the first day and 7, 14, 21 and 28 days after CTX+IRI infusion. RESULTS The median magnesium basal value showed a statistically significant decrease after the start of CTX+IRI treatment (at 28 days, P < 0.0001). Patients with an early decrease of magnesium levels >50% compared with the basal level had a higher tumor response rate (55.8% versus 16.7%, P < 0.0001), a longer TtP (6.3 versus 3.6, P < 0.0001) and a longer median OS (11.0 versus 8.1, P = 0.002). CONCLUSIONS We have shown that early hypomagnesemia could be a predictor of efficacy and outcome in those patients. Magnesium circulating level is an easy and inexpensive biomarker to routinely be detected in patients treated with cetuximab.
Collapse
Affiliation(s)
- B Vincenzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - S Galluzzo
- Department of Medical Oncology, University Campus Bio-Medico, Rome.
| | - D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - L Rocci
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - F Loupakis
- Unit of Medical Oncology, Azienda-Ospedaliero Universitaria Pisana, University of Pisa, Pisa
| | - P Correale
- Section of Medical Oncology, Department "Giorgio Segre" of Pharmacology, University of Siena, Siena
| | - R Addeo
- Oncology Department, "S. Giovanni di Dio" Hospital, Frattaminore
| | - A Zoccoli
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - A Napolitano
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - F Graziano
- Unit of Medical Oncology, Hospital of Pesaro, Pesaro
| | - A Ruzzo
- Section of Biochemistry and Molecular Biology "G. Fornaini", Department of Biomolecular Sciences, University of Urbino, Urbino
| | - A Falcone
- Section of Medical Oncology, Department "Giorgio Segre" of Pharmacology, University of Siena, Siena
| | - G Francini
- Oncology Department, "S. Giovanni di Dio" Hospital, Frattaminore
| | - G Dicuonzo
- Laboratory Medicine, University Campus Bio-Medico, Rome, Italy
| | - G Tonini
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| |
Collapse
|
23
|
Vincenzi B, Santini D, Galluzzo S, Loupakis F, Correale P, Addeo R, Del Prete S, Falcone A, Francini G, Tonini G. Early magnesium modifications as a surrogate markers of efficacy of cetuximab-based anticancer treatment in KRAS wild-type colorectal cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Remondo C, Tagliaferri P, Rotundo M, Tassone P, Del Vecchio M, Migali C, Francini G, Correale P. 1326 Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70499-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
25
|
Remondo C, Migali C, Martellucci I, Carbone F, Ricci V, Addeo R, Del Prete S, Fulfaro F, Francini G, Correale P. Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19083 Background: Chemotherapy efficacy in advanced non small cell lung cancer (NSCLC) patients may be augmented if combined with bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF) with anti-angiogenetic activity. Metronomic chemotherapy is a newest approach which employs cytotoxic drugs at lower doses with very close and regular administrations, which has shown anti-angiogenetic effects, epigenetic attenuation of cancer phenotype and immune-modulation. Metronomic chemotherapy with cisplatinum and oral etoposide (mPE) has been tested in NSCLC patients with promising results. We have thus investigated a newest biochemotherapy regimen with mPE + bevacizumab (mPEBev regimen) in advanced NSCLC patients. Methods: This is a phase IB/II trial designed to evaluate toxicity, anti-tumor and biological activity of bevacizumab given at escalating doses in combination with mPE chemotherapy. Twenty-six patients with inoperable NSCLC and an ECOG≤2 were enrolled in the study and received every 21 days, iv. cisplatinum (30 mg/sqm, days 1–3), oral etoposide (50 mg/sqm, days 1–15) and bevacizumab (day 3) at different dose levels (no antibody/control group; 2.5; 5; 7.5; and 10 mg/kg). Results: The treatment resulted very active in those patients who received bevacizumab with a 95% objective response rate (19/20), with a median time to progression of 7.55 months. There were two early deaths at higher bevacizumab dosages: one due to a cardiovascular accident (7.5 mg/kg) and another to lung hemorrhage (10mg/kg). We reported also 4 cases of psychic depression and 4 cases of pneumonia which evolved into lung cavitation. A magnetic resonance monitoring showed a significant treatment-related blood perfusion reduction in the tumor site. It was also observed a progressive decrease in VEGF, thrombospondin-1 levels which were not dependent upon bevacizumab dose and were not observed in the controls. Conclusions: mPEBev regimen resulted very active in advanced NSCLC patients. Our metronomic biochemotherapy regimen with lower bevacizumab doses (2.5–5 mg/Kg) deserves to be investigated in further phase II-III trials. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Remondo
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - C. Migali
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - I. Martellucci
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - F. Carbone
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - V. Ricci
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - R. Addeo
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - S. Del Prete
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - F. Fulfaro
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - G. Francini
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| | - P. Correale
- Medical Oncology Siena University, Siena, Italy; Radiology, Siena, Italy; Radiology, Siena, Italy; Medical Oncology Section, Frattaminore, Italy; Medical Oncology Section, Frattaminore, Italy; University of Palermo, Palermo, Italy
| |
Collapse
|
26
|
Correale P, Tagliaferri P, Del Vecchio MT, Remondo C, Migali C, Tsang KY, Rotundo MS, Fulfaro F, Tassone P, Francini G. Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3045 Background: GOLFIG is a novel chemoimmunotherapy regimen, combining gemcitabine, oxaliplatin, 5-FU/FA with immunoadjuvant GM-CSF and aldesleukine, which resulted safe and very active in colon cancer patients. Antitumor activity and immunity feedback to the treatment resulted strictly correlated. The best outcome was observed in patients showing autoimmunity signs, rise in central-memory-T cells, and decline in peripheral and tumor infiltrating immuno-regulatory T (Treg) cells. On these bases, we investigated a possible correlation between Treg tumor infiltration at diagnosis and clinical outcome of these patients. Methods: An immunohistochemistry study was carried out to quantify the infiltration of Treg (FoxP3+) lymphocytes in tumor samples of 41 colon cancer patients who received FOLFOX-4 chemotherapy or GOLFIG chemo-immunotherapy as enrolled in the ongoing phase III GOLFIG-2 trial. Treg tumor infiltration score (range 0 to 5) was then correlated with survival (OS) and time to progression (TTP). Results: A higher Treg tumor infiltration score (score 3–5) was associated to a longer OS and TTP in the whole patient population (high vs low score; TTP=18 vs 9.4 months; p=0.002; OS=55.7 vs 28.9 months; p=0.001); however, those patients with high tumor infiltration of FoxP3+-T cells who received GOLFIG regimen showed the most favorable outcome (high vs low score; TTP=20.8 vs 11.6 months; p=0.04; OS=68.1 vs 41 months; p=0.04). A Cox regression model demonstrated in these patients that a high Treg tumor infiltration score is an independent variable of long survival and prolonged TTP. Conclusions: Our results suggest that GOLFIG chemoimmunotherapy is highly effective in colon carcinoma patients with high FoxP3+ infiltration score and that Treg-tumor infiltration score may be a favorable prognostic marker in colon cancer patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Correale
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - P. Tagliaferri
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - M. T. Del Vecchio
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - C. Remondo
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - C. Migali
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - K. Y. Tsang
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - M. S. Rotundo
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - F. Fulfaro
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - P. Tassone
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| | - G. Francini
- Medical Oncology Siena University, Siena, Italy; Medical Oncology Unit, Catanzaro, Italy; Patology Section, Siena, Italy; Laboratory Tumor Immunology and Biology, Bethesda, MD; University of Palermo, Palermo, Italy
| |
Collapse
|
27
|
Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J Chemother 2008; 20:278-81. [PMID: 18467257 DOI: 10.1179/joc.2008.20.2.278] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
GOLFIG-1 chemo-immunotherapy is a new translational anticancer regimen based on the combined use of gemcitabine, oxalipatin, levofolinic acid and infusional 5-fluorouracil together with the subcutaneous administration immunoadjuvant cytokines (GM-CSF and ultra low dose IL-2). This regimen, tested in a phase II trial, was safe and very active in patients with metastatic colorectal carcinoma and it has been shown to have powerful immunobiological activity. Treatment with the GOLFIG regimen resulted in the induction of a colon cancer specific cell mediated immune response associated with a significant reduction in the percentage of peripheral regulatory T (T(reg)) cells, a very immunosuppressive lymphocyte subset which is commonly over-represented in cancer patients. These cells are able to prevent the occurrence of autoimmunity in response to immunological stimuli, thus their malfunctioning has been associated with the occurrence of auto-immune diseases but may also be responsible for more efficient anticancer immune reaction. In this manuscript we describe a clinical case concerning a patient with metastatic colon carcinoma who responded to the GOLFIG regimen, showed symptoms of autoimmunity [Discoid Lupus Erythematosus (DLE)] and had a very long survival.
Collapse
Affiliation(s)
- P Correale
- Section of Medical Oncology, Department of Clinical Medicine and Immunological Sciences, Siena University School of Medicine, Siena, Italy
| | | | | | | | | | | |
Collapse
|
28
|
Francini G, Paolelli L, Francini E, Pascucci A, Manganelli A, Salvestrini F, Petrioli R. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. Eur J Surg Oncol 2008; 34:216-21. [PMID: 17502132 DOI: 10.1016/j.ejso.2007.03.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2007] [Accepted: 03/20/2007] [Indexed: 11/15/2022] Open
Abstract
AIMS Most patients with stage T3-T4 prostate cancer experience disease relapse despite radiation and/or hormonal therapy, and their management remains controversial. We investigated the feasibility of, and the pathological response induced by neoadjuvant chemo-hormonal treatment in men with clinical stage T3/T4. METHODS Fifteen patients underwent neoadjuvant therapy consisting of weekly intravenous infusions of epirubicin 30mg/m(2) and total androgen blockade (TAB) for three months before undergoing radical prostatectomy, after which all received locoregional conformal radiotherapy (66Gy) and then continued with TAB and three additional months of epirubicin. RESULTS After neoadjuvant therapy, PSA levels decreased in all 15 patients and became undetectable in two. None of the patients achieved a complete pathological response, but a 35-75% reduction in tumour size was observed in all cases, and all the patients were able to undergo successful prostatectomy. Pathological assessments of the surgical specimens revealed negative margins in 13 patients. After a median follow-up of 34 months (range 11-62), 14 patients (93%) are still clinically and biochemically disease free. No grade 3 or 4 complications occurred. CONCLUSION This study suggests that neoadjuvant treatment with epirubicin and TAB is feasible and well tolerated in patients with clinical stage T3-T4 prostate cancer.
Collapse
Affiliation(s)
- G Francini
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy.
| | | | | | | | | | | | | |
Collapse
|
29
|
Correale P, Tagliaferri P, Montagnani F, Remondo C, Intrivici C, Fulfaro F, Tsang KY, Tassone P, Rotundo MS, Venuta S, Francini G. Autoimmunity predicts prolonged survival in colon cancer patients undergoing GOLFIG biochemotherapy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14542 Background: A multi-center phase II trial has been designed to evaluate toxicity, anti-tumour and immune-biological activity of the bio-chemotherapy GOLFIG regimen in advanced colorectal cancer (A-CRC). Methods: The trial involved 46 patients (34/46 2nd line or more). The biweekly GOLFIG regimen consisted of gemcitabine (1,000 mg/m2, day 1), oxaliplatin (85 mg/m2, day 2), levofolinic acid (100 mg /m2, day 1,2) and 5-FU (400 mg/m2 as a bolus, and 800 mg/m2 as 24 hour infusion, days 1,2) followed by sc GM-CSF (100 μg, days 3 to 8) and sc IL-2 (0.5 X 106 IUs twice a day, days 9 to 14). Results: GOLFIG regimen was well tolerated and resulted very active (ORR = 56.5%; disease control = 91.3%), fulfilling the pre-selected (40–60%) target of activity, with a promising TTP [12.26 months, 95% CI; 9.2–15.2 mo.] and OS [18.76 months, 95% CI; 15.2–22.3 mo.]. We detected a significant rise in lymphocyte number and colon cancer-specific cytotoxic T cells (CTLs) paralleled by a reduction in suppressive T-regulatory CD4+CD25+ FoxP3+ lymphocytes -Treg. Self-limiting autoimmunity (AI) occurred in 6 (14%) patients. 1 patient developed cutaneous lesions, with pathological diagnosis of Discoid Lupus Erythematosus (DLE), while 5 other presented a mono / oligoarticular arthritis mainly localized at the knees, elbows, shoulders and fingers with signs of synovitis (pain and swelling) paralleled by a significant increase of inflammatory markers (ESR, C-RP and rheumatoid factor). Subgroup analysis disclosed a mean time to progression of 23.8 months (95% CI; 12.1–35.56 mo.) and an overall survival of 31.83 months (95% CI; 19.9–43.7 mo.) in the 6 AI patients, significantly longer than in patients who did not develop AI [TTP and OS respectively 10.52 (95% CI; 7.7–13.3) and 16.8 months (95% CI; 13.3–20.2)], P ≤ 0.0039 and 0.0080. 5/6 AI patients are still alive and 3 have so far achieved a survival of 37, 41 and 50 months. Conclusions: The GOLFIG regimen exerts immunological and anti-tumour activity and has manageable toxicity in A-CRC. The occurrence of AI is predictive of a favourable outcome. These results provided the rationale for a presently ongoing phase III trial aimed to compare the efficacy of GOLFIG vs. FOLFOX-4 regimen as first line treatment in A- CRC patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Correale
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - P. Tagliaferri
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - F. Montagnani
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - C. Remondo
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - C. Intrivici
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - F. Fulfaro
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - K. Y. Tsang
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - P. Tassone
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - M. S. Rotundo
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - S. Venuta
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| | - G. Francini
- University of Siena, Siena, Italy; T. Campanella Cancer Center, Magna Graecia Univ., Catanzaro, Italy; National Cancer Institute, Bethesda, MD; University of Palermo, Palermo, Italy
| |
Collapse
|
30
|
Correale P, Sciandivasci A, Intrivici C, Pascucci A, Del Vecchio MT, Marsili S, Savelli V, Voltolini L, Di Bisceglie M, Guarnieri A, Gotti G, Francini G. Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer 2007; 96:1343-7. [PMID: 17437022 PMCID: PMC2360193 DOI: 10.1038/sj.bjc.6603734] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
We report the results of a phase II trial in patients with metastatic endocrine tumours from different sites, which aimed to evaluate the anti-tumour activity and toxicity of a cisplatinum and etoposide regimen administered in combination with the somatostatin agonist lanreotide given in slow release formulation. Between January 1999 and November 2003, 27 patients with histological diagnoses of endocrine tumours with different degrees of differentiation, excluding well differentiated carcinoid neoplasms, received intravenous (i.v.) administration of cisplatinum (30 mg m−2) and etoposide (100 mg m−2) on days 1–3 and intramuscular administration of 60 mg lanreotide on day 1, in a 21-day cycle. All of the patients were evaluable for toxicity and response. The treatment was very well tolerated as no grade 4 toxicity was observed. Four patients achieved a complete response, six a partial response, 12 experienced disease stabilisation and five disease progression. The average time to progression and to survival were 9 and 24 months respectively. These results suggest that this chemo-hormone therapy regimen is well tolerated and active in patients with non-well differentiated endocrine tumours.
Collapse
Affiliation(s)
- P Correale
- Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - A Sciandivasci
- Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - C Intrivici
- Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - A Pascucci
- Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - M T Del Vecchio
- Medical Pathology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - S Marsili
- Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - V Savelli
- Second Division of General Surgery, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - L Voltolini
- Division of Thoracic Surgery, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - M Di Bisceglie
- Division of Thoracic Surgery, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - A Guarnieri
- Second Division of General Surgery, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - G Gotti
- Division of Thoracic Surgery, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
| | - G Francini
- Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
- E-mail:
| |
Collapse
|
31
|
Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007; 40:205-10. [PMID: 16904960 DOI: 10.1016/j.bone.2006.06.027] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2006] [Revised: 06/24/2006] [Accepted: 06/30/2006] [Indexed: 11/19/2022]
Abstract
Recently the third generation aromatase inhibitors have proved their efficacy and tolerability compared with tamoxifen in the adjuvant treatment of women with hormone responsive early breast cancer. However, there is some concern about the possible negative impact of these drugs on bone. The aim of the study was to evaluate the effects of the steroidal aromatase inactivator exemestane on bone turnover markers and on bone mineral density (BMD). Seventy postmenopausal women (62.0+/-8.9 years) with completely resected breast cancer and who were disease-free following 2-3 years on tamoxifen were randomly assigned to continue tamoxifen (n=36) or switch to exemestane (n=34). Sixty-one patients completed the 2-year study period. Bone alkaline phosphatase (B-ALP) and the carboxy-terminal telopeptide of type I collagen (CTX) were measured at baseline and after 3, 6, 9, 12, 18 and 24 months. BMD at lumbar spine (BMD-LS), at femoral neck (BMD-FN), at total hip (BMD-T) and at whole body (BMD-WB) were measured at 6-monthly intervals. Exemestane-treated women showed significant (p<0.01) increases with respect to baseline in both B-ALP and CTX. The difference between the 2 groups reached the statistical significance at month 6 for CTX (p<0.05) and at month 9 for B-ALP (p<0.01). Moreover, the exemestane-treated women showed an early decrease in PTH serum levels (-20.4%, p<0.01 at month 6). In the E group, the percentage changes were -2.37 (p<0.05) BMD-LS, -1.24 (p<0.05) BMD-FN, -1.1 (n.s.) BMD-T, -1.03 (n.s.) BMD-WB at month 12 and -2.99 (p<0.01) BMD-LS, -1.92 (p<0.01) BMD-FN, -2.01 (p<0.05) BMD-T, -1.3 (n.s.) BMD-WB at month 24. The tamoxifen group did not show significant changes in BMD. The differences between the two groups were significant at all skeletal sites except BMD-WB. Our data suggest that switching postmenopausal women from tamoxifen to exemestane causes a marked increase in bone turnover markers with a consequent reduction in BMD. These findings could be due to both the direct effect of exemestane and to the loss of the protective effect of tamoxifen. Therefore, the postmenopausal women switched from tamoxifen to exemestane should be monitored for bone loss especially if other risk factors for osteoporosis are present.
Collapse
Affiliation(s)
- S Gonnelli
- Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100 Siena, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, Di Bisceglie M, Giorgi G, Gotti G, Francini G. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 2006; 16:133-40. [PMID: 16786136 DOI: 10.3892/or.16.1.133] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The aim of this pilot phase II trial was to investigate the toxicity and anti-tumour activity of a novel metronomic regimen of weekly cisplatin (CDDP) and oral etoposide (VP16) in high-risk patients with advanced NSCLC. The study enrolled 31 high-risk patients (27 men and 4 women aged 16-82 years; mean, 64.3) with NSCLC (18 stage IIIB and 13 stage IV) and an ECOG performance status of < or = 3, all of whom received weekly CDDP 30 mg/m2 iv on days 1, 8, 14 and 28 of each cycle and oral daily etoposide 50 mg/m2 on 21 of the 28 days. The most frequent adverse events were grade III leukopenia and anemia; nevertheless, three patients died of pulmonary embolism after 2, 3 and 6 weeks of treatment. The objective response (OR) rate was 45.2% (2 complete and 12 partial), and the disease control rate was 58.1% (14 ORs and 4 disease stabilisations). The mean time to progression and survival were respectively nine months (95% CI, 6.3-15.8 months) and thirteen months (95% CI, 9.1-20.5 months). Pharmacological analysis showed that this metronomic regimen allows a much greater median monthly area under the curve of CDDP and VP16 than conventional treatment schedules. Our findings also suggest that this treatment schedule may affect tumour growth and neoangiogenesis by changing peripheral blood vascular-endothelial growth factor levels. These preliminary results indicate that our metronomic regimen is well tolerated and active, even in patients with a very poor prognosis.
Collapse
Affiliation(s)
- P Correale
- Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, I-53100 Siena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 2006; 95:153-8. [PMID: 16835585 PMCID: PMC2360614 DOI: 10.1038/sj.bjc.6603258] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment. Although many of the adverse effects associated with exemestane and tamoxifen have been analysed, there are no comparative data concerning body weight and body composition. The aim of this randomised study was to evaluate the longitudinal changes in body composition and lipid profiles in postmenopausal women switched from tamoxifen to exemestane. In total, 60 overweight or obese postmenopausal patients were enrolled. Their anthropometric data, body composition, including fat mass (FM) and fat-free mass (FFM), and lipid profiles, caloric intake and physical activity were assessed 1 week before randomisation, and 6 and 12 months later. In all, 55 patients (27 on tamoxifen and 28 on exemestane) completed the 1-year study period. Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group; the between-group difference was statistically significant (P<0.01). The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group; the between-group difference was statistically significant (P<0.05). Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05), and low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period. Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
Collapse
Affiliation(s)
- G Francini
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Siena, Italy.
| | | | | | | | | | | | | |
Collapse
|
34
|
Correale P, Remondo C, Montagnani F, Rotundo MS, Marsili S, Laplaca M, Tassone P, Tagliaferri P, Venuta S, Francini G. Chemo-immunotherapy regimen with gemcitabine + FOLFOX 4 (GOLF) followed by subcutaneous (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). Results from a multicenter phase II trial in colon carcinoma patients. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3587] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3587 We have recently described a poly-chemotherapy (GOLF) regimen that: A) is active in colon carcinoma patients as second line of therapy; B) induces high levels of necrosis and apoptosis in colon cancer cells; C) up-regulates the expression and release of heat shock proteins (HSP)-70 and -90 and tumour-associated antigens (2,3); and D) down-regulates tumour cell resistance to the death signals of cytotoxic-T-lymphocytes.These effects represented the rationale for projecting GOLFIG regimen. Here we describe the results of a multi-center translational phase II trial designed to evaluate the toxicity, anti-tumour activity of a novel regimen designated as GOLFIG-1, composed by the GOLF poly-chemotherapy followed by the subcutaneous (sc.) administration of GM-CSF and low-dose IL-2 in colorectal carcinoma patients. The study involved 37 patients (21M and 16F, mean age 62.5 years), 24 of whom had received a previous line of treatment, and 24 had liver involvement. All the patients received biweekly chemotherapy with gemcitabine (1g/m2, day 1 and 15), oxaliplatin (85 mg/m2, day 2 and 16), levo-folinic acid (100 mg /m2, day 1, 2, 15, 16) and 5-Fluorouracil (400 mg/m2 as a bolus, and 800 mg/m2 as 24 hour infusion, days 1, 2, 15, 16). These patients also received sc GM-CSF (100 μg, day 3 to 8) followed by sc IL-2 (0.5 X 106 IUs twice a day from day 9 to 14 and from 17 to 29). The treatment was well tolerated and very active in colon carcinoma patients, with high objective response (64.9%) and disease control rates (97.3%), with an average time to progression of 12.94 months (CI 95%: 9.98–15.91). An immunological study confirmed the immunological response to colon carcinoma antigen, a significant reduction in suppressive regulatory T lymphocytes (CD4+CD25+T-reg) and a significant reduction of VEGF levels reported in a previous study. In conclusion, these results suggest that the GOLFIG regimen exerts strong immunological and anti-tumour activity in colorectal cancer patients. A randomized phase III trials aimed to compare the efficacy of GOLFIG-1 with FOLFOX-4 regimen in patients with advanced colorectal carcinoma is presently ongoing. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Correale
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - C. Remondo
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - F. Montagnani
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - M. S. Rotundo
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - S. Marsili
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - M. Laplaca
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - P. Tassone
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - P. Tagliaferri
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - S. Venuta
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| | - G. Francini
- University of Siena, Siena, Italy; University of Catanzaro, Catanzaro, Italy
| |
Collapse
|
35
|
Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Intrivici C, La Placa M, Aquino A, Bonmassar E, Francini G. Immunological and anti-tumor activity of a novel a chemo-immunotherapy regimen with gemcitabine, oxaliplatin, levo-folinic acid, and 5-fluorouracil followed by GM-CSF and Interleukin-2 in patients with metastatic colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Correale
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - M. G. Cusi
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - K. Y. Tsang
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - M. T. Del Vecchio
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - S. Marsili
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - C. Intrivici
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - M. La Placa
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - A. Aquino
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - E. Bonmassar
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| | - G. Francini
- Sect of Oncology Siena Univ Sch of Medici, Siena, Italy; Section of Virology Siena Univ, Siena, Italy; Lab of Tumor Immunology and Biology, Bethesda, MD; Section of Pathology Siena Univ, Siena, Italy; Section Of Oncology Siena Univ, Siena, Italy; Oncology and Pharmacology Section, Rome Univ, Rome, Italy
| |
Collapse
|
36
|
Francini G, Petrioli R. Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 2004. [PMCID: PMC2409856 DOI: 10.1038/sj.bjc.6602017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Sargent DJ, Wieand S, Benedetti J, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G, De Gramont A, Goldberg RM. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3502] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. J. Sargent
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - S. Wieand
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - J. Benedetti
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - R. Labianca
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - D. G. Haller
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - L. E. Shepherd
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - J. F. Seitz
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - G. Francini
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - A. De Gramont
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| | - R. M. Goldberg
- NCCTG, Mayo Clinic, Rochester, MN; NSABP Statistical Center, Pittsburg, PA; SWOG Statistical Center, Seattle, WA; Ospedali Riuniti, Bergamo, Italy; University of Pennsylvania Cancer Center, Philadelphia, PA; NCIC-CTG, Kingston, ON, Canada; University of the Mediterranean, Marseilles, France; University of Siena, Siena, Italy; Hospital Saint Antoine, Paris, France; University of North Carolina, Chapel Hill, NC
| |
Collapse
|
38
|
Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, Ceciarini F, Micheli L, Nencini C, Neri A, Vuolo G, Guarnieri A, Abbruzzese A, Prete SD, Giorgi G, Francini G. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer 2004; 90:1710-4. [PMID: 15150625 PMCID: PMC2409742 DOI: 10.1038/sj.bjc.6601783] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Previous results suggest that GEM affects 5-fluorouracil (5-FU) metabolism and pharmacokinetics in cancer patients, while combined with oxaliplatin, levo-folinic acid, and 5-FU (GOLF regimen), at doses achievable in cancer patients, determines high cytotoxic and proapoptotic antitumour activity in colon cancer cells in vitro. On these bases we designed a phase I-II clinical trial testing the GOLF regimen in patients with metastatic colorectal carcinoma, who had received at least a prior line of chemotherapy. In total, 29 patients (20 males and nine females) enrolled in the study received every 2 weeks, gemcitabine (patients #1-3 received 600 mg m(-2); patients # 4-6 received 850 mg m(-2); while patients # 7-29 received 1000 mg m(-2)) on the day 1, levo-folinic acid (100 mg m(-2)) on the days 1 and 2; 5-fluorouracil (400 mg m(-2)) in bolus injection, followed by a 22-h continuous infusion (800 mg m(-2)) on the days 1 and 2, and oxaliplatin (85 mg m(-2)), 6 h after the 5-FU bolus on day 2. The most frequent side effect was grade I-II haematological toxicity. In total, 28 patients were evaluable for response: three achieved a complete response, nine a partial response, 10 had a stable disease, and six progressed. The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months. Our GOLF combination is well tolerated and seems promising for the treatment of advanced colorectal cancer.
Collapse
Affiliation(s)
- P Correale
- Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
| | - S Messinese
- Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
| | - M Caraglia
- Oncology Operative Unit, Frattamaggiore Hospital, Italy
| | - S Marsili
- Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
| | - A Piccolomini
- Surgical Science Department, University of Siena School of Medicine, Italy
| | - R Petrioli
- Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
| | - F Ceciarini
- Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
| | - L Micheli
- ‘Giorgio Segre’ Pharmacology Department, University of Siena School of Medicine, Italy
| | - C Nencini
- ‘Giorgio Segre’ Pharmacology Department, University of Siena School of Medicine, Italy
| | - A Neri
- Surgical Science Department, University of Siena School of Medicine, Italy
| | - G Vuolo
- Surgical Science Department, University of Siena School of Medicine, Italy
| | - A Guarnieri
- Surgical Science Department, University of Siena School of Medicine, Italy
| | - A Abbruzzese
- Biochemistry Section, Second University of Naples, Naples, Italy
| | - S D Prete
- Oncology Operative Unit, Frattamaggiore Hospital, Italy
| | - G Giorgi
- ‘Giorgio Segre’ Pharmacology Department, University of Siena School of Medicine, Italy
| | - G Francini
- Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
- Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy. E-mail:
| |
Collapse
|
39
|
Petrioli R, Sabatino M, Fiaschi AI, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 2004; 90:306-9. [PMID: 14735168 PMCID: PMC2409570 DOI: 10.1038/sj.bjc.6601521] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
Collapse
Affiliation(s)
- R Petrioli
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
| | - M Sabatino
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
| | - A I Fiaschi
- Department of Pharmacology, University of Siena, Siena, Italy
| | - S Marsili
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
| | - D Pozzessere
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
| | - S Messinese
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
| | - P Correale
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
| | - S Civitelli
- Clinical Surgery; University of Siena, Siena, Italy
| | - G Tanzini
- Clinical Surgery; University of Siena, Siena, Italy
| | - F Tani
- General Surgery; University of Siena, Siena, Italy
| | - A De Martino
- General Surgery; University of Siena, Siena, Italy
| | - G Marzocca
- General Surgery; University of Siena, Siena, Italy
| | - M Lorenzi
- General Surgery; University of Siena, Siena, Italy
| | - G Giorgi
- Department of Pharmacology, University of Siena, Siena, Italy
| | - G Francini
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy. E-mail:
| |
Collapse
|
40
|
Correale P, Messinese S, Marsili S, Ceciarini F, Pozzessere D, Petrioli R, Sabatino M, Cerretani D, Pellegrini M, Di Palma T, Neri A, Calvanese A, Pinto E, Giorgi G, Francini G. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 2003; 89:239-42. [PMID: 12865908 PMCID: PMC2394244 DOI: 10.1038/sj.bjc.6601045] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Pancreatic adenocarcinoma is a common disease considered to be poorly responsive to antiblastic treatment. Recent clinical and preclinical results suggest that a combined treatment of gemcitabine (GEM), 5-flurouracil (5-FU) and folinic acid (FA) offers a clinical benefit in patients with advanced pancreas adenocarcinoma. The aim of this phase II clinical trial was to evaluate the antitumour activity and toxicity of a novel biweekly schedule of this combination in patients with pancreatic adenocarcinoma. A total of 42 patients received a 30 min infusion of FA (100 mg m(-2)) and 5-FU (400 mg m(-2)) (FUFA) on days 1-3, and GEM 1000 mg m(-2) on day 1 every 15 days. We observed 13 objective responses (two complete, 11 partial) and 23 stable diseases. The median time to progression was 9.75 months (95% Confidence Interval (CI), 6.88-12.62) and the median overall survival was 13.10 months (95% CI 9.64-16.56). There were seven cases of each grade III gastroenteric and haematological toxicity. The GEM plus FUFA combination appears to be well tolerated and very active in patients with pancreatic carcinoma.
Collapse
Affiliation(s)
- P Correale
- Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Scardino A, Correale P, Firat H, Pellegrini M, Kosmatopoulos K, Opolon P, Alves P, Zurbriggen R, Glück R, Lemonnier FA, Francini G, Cusi MG. In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse. Br J Cancer 2003; 89:199-205. [PMID: 12838324 PMCID: PMC2394210 DOI: 10.1038/sj.bjc.6601028] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Parathyroid hormone-related protein (PTH-rP), a secreted protein produced by prostate carcinoma and other epithelial cancers, is considered a key agent for the development of bone metastases. We investigated the construct GC90/IRIV, composed of immunopotentiating reconstituted influenza virosomes (IRIV) containing PTH-rP gene plasmids (GC90), as a potential tool for human anticancer immunotherapy into humanised mice transgenic for HLA-A(*)02.01, the human-beta2 microglobulin, and the human CD8alpha molecule. Intranasal administration of GC90/IRIV resulted in the induction of a PTH-rP-specific multiepitope cytotoxic T-cell (CTL) response. Cytotoxic T cells derived from vaccinated mice were capable of lysing in vitro syngenic murine PTH-rP transfectants and human HLA-A((*))02.01(+)/PTH-rP(+) prostate carcinoma LNCaP cells as well. The immune response capacity and the absence of any sign of toxicity and/or autoimmunity in vivo suggest the GC90/IRIV vaccine as a valid tool for active specific immunotherapy of human cancers and metastases overexpressing PTH-rP.
Collapse
Affiliation(s)
- A Scardino
- INSERM U. 487, IGR, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Roviello F, Pinto E, Francini G, Giorgi G. Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer 2003; 39:1547-51. [PMID: 12855261 DOI: 10.1016/s0959-8049(03)00361-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A number of recent clinical trials testing the combination of 5-fluorouracil (5-FU) and gemcitabine in patients with advanced pancreatic adenocarcinoma have shown a significant clinical response rate, but also significant toxicity. As the two antimetabolites may interact at several biochemical levels along their pathways of activation, we investigated whether gemcitabine (GEM) affects 5-FU pharmacokinetics in cancer patients. Thus, we compared 5-FU pharmacokinetics in two groups of patients with various cancers who received the same schedule of 5-FU and folinic acid (FUFA), with or without GEM. There was a significant increase in systemic (5-FU) exposure and toxicity in the FUFA plus GEM group. Our finding may be useful in designing future studies of the combination in order to reduce the occurrence of side-effects and to maximise the antitumour activity.
Collapse
Affiliation(s)
- P Correale
- Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Petrioli R, Fiaschi AI, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Manganelli A, Salvestrini F, Francini G. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 2002; 87:720-5. [PMID: 12232753 PMCID: PMC2364259 DOI: 10.1038/sj.bjc.6600525] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2002] [Revised: 07/11/2002] [Accepted: 07/15/2002] [Indexed: 01/22/2023] Open
Abstract
The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metastatic hormone-resistant prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-min intravenous infusions of epirubicin 30 mg m(2) of body surface area. The primary end-point was palliative response, defined as a reduction in pain intensity and an improvement in performance status. The secondary end-points were the duration of the palliative response, quality of life and survival. Fifty-seven (44%) of the 131 evaluable patients met the primary criterion of palliative response after six treatment cycles and 73 (56%) after 12 cycles; the median duration of the response was 9 months (range 1-11). The median global quality of life improved in 52% of the patients after six cycles and in 68% after 12 cycles. The 12- and 18-month survival rates were respectively 56 and 31%, with a median survival of 13+ months (range 1-36). The treatment was well tolerated: grade 3 neutropenia was observed in 8% of the patients, grade 3 anaemia in 7%, and grade 3 thrombocytopenia in 3%. None of the patients developed grade 4 toxicity or congestive heart failure. Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival.
Collapse
Affiliation(s)
- R Petrioli
- Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Correale P, Cusi MG, Sabatino M, Micheli L, Pozzessere D, Nencini C, Valensin PE, Petrioli R, Giorgi G, Zurbriggen R, Gluck R, Francini G. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur J Cancer 2001; 37:2097-103. [PMID: 11597390 DOI: 10.1016/s0959-8049(01)00241-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We investigated influenza virosomes as a TAA-gene delivery system for use in TAA-directed anti-cancer vaccine therapy. An engineered plasmid (GC90) expressing the parathyroid hormone-related peptide (PTH-rP), a protein secreted by prostate and lung carcinoma cells, was included in influenza virosomes (GC90V). The ability of GC90V to elicit a PTH-rP-specific cytotoxic T cell (CTL) response was demonstrated in BALB/c mice immunised with intranasal (i.n.) GC90V+/-adjuvant subcutaneous (s.c.) interleukin-2 (IL-2). A PTH-rP-specific CTL response with antitumour activity was also demonstrated in human peripheral blood mononuclear cells (PBMC) stimulated in vitro with GC90V infected autologous dendritic cells (DC). These results provide a rationale for investigating GC90V in clinical trials of anticancer vaccine therapy.
Collapse
Affiliation(s)
- P Correale
- Medical Oncology Division, Medicine School, Siena University, 53100, Siena, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Br J Cancer 2001; 85:1722-30. [PMID: 11742494 PMCID: PMC2363980 DOI: 10.1054/bjoc.2001.2136] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Bone metastases are one of the most common events in patients with prostate carcinoma. PTH-rP, a protein produced by prostate carcinoma and other epithelial cancers, is a key agent for the development of bone metastases. A PTH-rP-derived peptide, designated PTR-4 was identified, which is capable to bind HLA-A2.1 molecules and to generate PTH-rP-specific cytotoxic T cell (CTL) lines from healthy HLA-A2.1(+) individual peripheral-blood-mononuclear-cells (PBMC). In this model, we investigated the in vitro possibility of generating an efficient PTH-rP specific CTL response by cyclical stimulations with IL-2 and PTR-4 peptide-pulsed autologous dendritic cells (DC), of HLA-A2.1(+) tumour infiltrating lymphocytes (TIL) derived from a patient with metastatic prostate carcinoma. A T cell line generated in this way (called TM-PTR-4) had a CD3(+), CD5(+), CD4(-), CD8(+), CD45(Ro+), CD56(-) immunophenotype and a HLA-A2.1 restricted cytotoxic activity to PTR-4-peptide pulsed CIR-A2 (HLA-A2.1(+)) target cells, PTH-rP(+)/HLA-A2.1(+) CIR-A2 transfected with PTH-rP gene, prostate carcinoma LNCaP cells, and autologous metastatic prostate cancer cells (M-CaP). These lymphocytes were not cytotoxic to HLA-A2.1(+) targets not producing PTH-rP, such as peptide-unpulsed CIR-A2 and colon carcinoma SW-1463, cell lines. Our results provide evidence that PTR-4 peptide-pulsed autologous DC may break the tolerance of human TIL against the autologous tumour by inducing a PTH-rP-specific CTL immune reaction. In conclusion PTR-4 peptide-pulsed autologous DC may be a promising approach for vaccine-therapy and antigen-specific CTL adoptive immunotherapy of hormone-resistant prostrate cancer.
Collapse
Affiliation(s)
- P Correale
- Division of Medical Oncology, 'Giorgio Segre', University of Siena, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091-7. [PMID: 11596588 DOI: 10.1056/nejmoa010957] [Citation(s) in RCA: 667] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Adjuvant chemotherapy is standard treatment for patients with resected colon cancer who are at high risk for recurrence, but the efficacy and toxicity of such treatment in patients more than 70 years of age are controversial. METHODS We performed a pooled analysis, based on the intention to treat, of individual patient data from seven phase 3 randomized trials (involving 3351 patients) in which the effects of postoperative fluorouracil plus leucovorin (five trials) or fluorouracil plus levamisole (two trials) were compared with the effects of surgery alone in patients with stage II or III colon cancer. The patients were grouped into four age categories of equal size, and analyses were repeated with 10-year age ranges (< or =50, 51 to 60, 61 to 70, and >70 years), with the same conclusions. The toxic effects measured in all trials were nausea or vomiting, diarrhea, stomatitis, and leukopenia. Patients in the fluorouracil-plus-leucovorin and fluorouracil-plus-levamisole groups were combined for the efficacy analysis but kept separate for toxicity analyses. RESULTS Adjuvant treatment had a significant positive effect on both overall survival and time to tumor recurrence (P<0.001 for each, with hazard ratios of death and recurrence of 0.76 [95 percent confidence interval, 0.68 to 0.85] and 0.68 [95 percent confidence interval, 0.60 to 0.76], respectively). The five-year overall survival was 71 percent for those who received adjuvant therapy, as compared with 64 percent for those untreated. No significant interaction was observed between age and the efficacy of treatment. The incidence of toxic effects was not increased among the elderly (age >70 years), except for leukopenia in one study. CONCLUSIONS Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects.
Collapse
|
47
|
Correale P, Sabatino M, Cusi MG, Micheli L, Nencini C, Pozzessere D, Petrioli R, Aquino A, De Vecchis L, Turriziani M, Prete SP, Sanguedolce R, Rausa L, Giorgi G, Francini G. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J Chemother 2001; 13:519-26. [PMID: 11760216 DOI: 10.1179/joc.2001.13.5.519] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
5-Fluorouracil (5-FU) is a pyrimidine antimetabolite active against colorectal carcinoma and other malignancies of the digestive tract. Over-expression or mutation of thymidylate synthase (TS), the target enzyme of the 5-FU metabolite, 5-fluorodeoxyuridine monophosphate, is strictly correlated with cancer cell resistance to 5-FU. On this basis we investigated whether TS is a potential target for active specific immunotherapy of human colon carcinoma, which acquires resistance to 5-FU. Three TS-derived epitope peptides which fit defined amino acid consensus motifs for HLA-A2.1 binding were synthesized and investigated for their ability to induce human TS-specific cytotoxic T cell (CTL) responses in vitro. CTL lines specific for each peptide were established by stimulating peripheral blood mononuclear cells (PBMC) from an HLA-A2.1+ healthy donor with autologous dendritic cells loaded with TS peptide. Specific CTL lines showed HLA-A2.1-restricted cytotoxicity in vitro to HLA-A2.1+ target cells pulsed with the specific TS peptide and to HLA-class I matching colon carcinoma target cells over-expressing TS enzyme after exposure to 5-FU. Recognition by CTL lines suggests that these TS peptides may be potential candidates for use in a peptide-based vaccine against 5-FU resistant colon carcinoma.
Collapse
Affiliation(s)
- P Correale
- Oncopharmacology Center, School of Medicine, University of Siena, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Francini G, Petrioli R, Gonnelli S, Correale P, Pozzessere D, Marsili S, Montagnani A, Lucani B, Rossi S, Monaco R, Manganelli A, Salvestrini F, Fiaschi AI. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer 2001; 92:1468-74. [PMID: 11745224 DOI: 10.1002/1097-0142(20010915)92:6<1468::aid-cncr1471>3.0.co;2-s] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND One of the greatest problems in treating advanced prostate carcinoma is monitoring the therapeutic response of bone metastases. As these metastases are mainly osteosclerotic and lead to a markedly increased bone calcium requirement that may give rise to an imbalance in calcium homeostasis, the authors investigated whether changes in calcium balance may be useful for evaluating the response of bone metastases to treatment. METHODS The study involved 268 prostate carcinoma patients: 142 in Stage A-C2 (International Union Against Cancer [UICC] staging system, 1998) and 126 with bone metastases who had failed to respond to hormone therapy and were receiving chemotherapy. Prostate-specific antigen (PSA), calcium and phosphate metabolism, and the main bone formation and resorption markers were all assayed before and after chemotherapy. RESULTS Of the 126 patients on chemotherapy, 109 were evaluable for response: according to standard criteria, 25 (23%) had improved, 43 (39.5%) were unchanged, and 41 (37.5%) had worsened. All of the improved and 16 unchanged patients had decreased PSA and bone marker levels and an increased urinary calcium/creatinine ratio (UCa/Cr); the worsened patients had increased PSA and bone marker levels, and their UCa/Cr decreased after only six treatment cycles. PSA and UCa/Cr were the biochemical markers whose changes showed the best agreement with treatment response. CONCLUSION The UCa/Cr ratio was the most useful marker of clinical response, mainly because it allowed an early decision to continue or to stop chemotherapy. Furthermore, UCa/Cr and PSA together identified a percentage of patients classified as unchanged on the basis of standard criteria but whose condition had actually improved.
Collapse
Affiliation(s)
- G Francini
- Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G, Giorgi G, Francini G. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer 2001; 37:892-902. [PMID: 11313178 DOI: 10.1016/s0959-8049(01)00063-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Experimental findings suggest that granulocyte-monocyte-colony stimulating factor (GM-CSF) synergistically interacts with interleukin-2 (IL-2) in generating an efficient antigen-specific immune response. We evaluated the toxicity, antitumour activity and immunobiological effects of human recombinant (hr)-GM-CSF and hr-IL-2 in 25 cancer patients who subcutaneously (s.c.) received hr-GM-CSF 150 microg/day for 5 days, followed by hrIL-2 s.c. for 10 days and 15 days rest. Two of the most common side-effects were bone pain and fever. Of the 24 patients evaluable for response, 3 achieved partial remission, 13 experienced stable disease, and 8 progressed. Cytokine treatment increased the number of monocytes, dendritic cells (DC), and lymphocytes (memory T cells) in the peripheral blood and enhanced the antigen-specific immunoreactivity of these patients. Our results show that the hr-GM-CSF and hr-IL-2 combination is active and well tolerated. Its biological activity may support tumour associated antigen (TAA)-specific anticancer immunotherapy by increasing antigen presenting cell (APC) activity and T cell immune competence in vivo.
Collapse
Affiliation(s)
- P Correale
- Division of Medical Oncology, University of Siena, Viale Bracci 11, 53100, Siena, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Correale P, Cusi G, Scardino A, Lemonnier F, Micheli L, Sabatino M, Pozzessere D, Petrioli R, Giorgi G, Francini G. Models of active specific immuno therapy of human malignancy bone metastases. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81077-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|